supported by National Natural Science Foundation of China-Shandong Joint Fund (No. U1606403);Innovation Project of Qingdao National Laboratory for Marine Science and Technology (No. 2015ASKJ02)。
In recent years, the strategy of inhibiting the interactions of p53 with murine double minute 2(MDM2)and murine double minute X(MDMX) has been proved to be a promising approach for tumor therapy.However, the poor prot...
supported by grants from the National Natural Science Foundation of China,No.21807112(to Xiang Li),No.82030062(to Wuyuan Lu),Nos.91849129 and 22077078(to Honggang Hu);Shanghai Rising-Star Program(to Xiang Li,China);supported by the U.S.Department of Energy,Office of Science,Office of Basic Energy Sciences under Contract No.DE-AC02-76SF00515;supported by the DOE Office of Biological and Environmental Research,and by the National Institutes of Health,National Institute of General Medical Sciences
Peptide inhibition of the interactions of the tumor suppressor protein P53 with its negative regulators MDM2 and MDMX activates P53 in vitro and in vivo,representing a viable therapeutic strategy for cancer treatment....
This work was supported in part by the Morningside Foundation,the Zhu Fund,and grants from the National Cancer Institute at the National Institutes of Health(RO1CA233558,R01CA167814,and R01CA125144)to Z.-M.Y.
A role of tumor-suppressive activity of p53 in the tumor microenvironment(TME)has been implicated but remains fairly understudied.To address this knowledge gap,we leveraged our MdmxS314A mice as recipients to investig...
The mouse double minute 4(MDM4)is emerging from the shadow of its more famous relative MDM2 and is starting to steal the limelight,largely due to its therapeutic possibilities.MDM4 is a vital regulator of the tumor su...
This work was supported by the Clinical Research Award of the First Affiliated Hospital of Xi’an Jiaotong University(XJTU1AF-CRF-2017-003)to Hou P and He WX.
Aim:Hepatocellular carcinoma(HCC)has emerged as one of the most commonly diagnosed forms of human cancer;yet,the current treatment for HCC is less effective than those used against other cancers.Transcription factor p...